7 Pet Care Stocks Worth Watching Right Now in November 2026
A seven-stock countdown spans pet pharmacies, insurance, specialty retail, pet food, diagnostics and animal-health pharmaceuticals across varied business models.
Pet care remains one of the more durable consumer themes for investors in November 2026. Owners increasingly treat pets as family, helping support recurring spending on food, treats, wellness, insurance and veterinary services even when household budgets are under pressure. The category is not immune to trade-downs or cost concerns, but its mix of necessities and services can make demand more resilient than many discretionary markets. The American Pet Products Association said U.S. pet industry spending reached $158 billion in 2025 and is positioned to continue growing in 2026.
The investment opportunity stretches across several distinct sub-segments. Pet food and treats offer branded, repeat-purchase demand; online and specialty retailers add convenience and autoship; veterinary services and diagnostics monetize preventive care; pharmaceuticals and parasiticides benefit from recurring treatment needs; and insurance can make larger medical bills more predictable. The humanization of pets, an aging pet population, omnichannel purchasing and expanding pet-health infrastructure are the structural forces tying these businesses together, although their margins and cyclicality differ considerably.
This countdown moves from rank #7 to rank #1, balancing each company’s depth of exposure to pet care with its business fundamentals. The list includes a pet pharmacy, an insurance specialist, retailers, branded pet-food companies and an animal-health pharmaceutical leader. A broader pet-health ecosystem is also emerging: Chewy’s expansion beyond e-commerce into higher-value services illustrates how engagement, convenience and recurring care can reinforce one another. The final ranking reflects both thematic relevance and the financial evidence available in our composite metrics.
Methodology brief. The screen covers US-listed companies with market capitalizations above $500 million and applies a two-step ranking process: depth of exposure to pet care comes first, followed by business fundamentals. Those fundamentals include valuation, profitability, growth, earnings execution, balance-sheet signals and analyst expectations. The article is presented as a countdown, so the best pick is reserved for #1 at the end. Market capitalization, quality grades and consensus figures are based on the latest available data for this November 2026 refresh, while individual company discussions emphasize recurring revenue potential, operating performance and execution risk.
What they do. The company operates an online and direct-response pet pharmacy serving dogs, cats and horses. PetMed Express sells prescription and non-prescription medications, flea and tick products, vitamins, supplements, treats and broader supplies through its website, mobile app, customer-support center and direct mail. Its focused pharmacy model gives it unusually direct exposure to recurring pet-health purchases, although it lacks the scale and breadth of the larger retailers and manufacturers in this group.
Why it fits. PetMed Express sits directly in the pharmaceuticals and parasiticides segment of pet care. Heartworm preventatives, flea and tick treatments, arthritis medicines, dermatology products and other specialty medications can generate repeat demand, while its food, beds and household supplies provide additional basket size. The company’s digital ordering and customer-support infrastructure also align with the category’s shift toward convenience, but the investment case depends heavily on restoring customer traction and profitability.
Numbers that matter. Revenue was $168.856 million, with year-over-year revenue down 19.9%. The company reported a 27.9% gross margin, but its operating margin was negative 15.19% and net margin was negative 17.34%; EBITDA was negative $18.588 million. TTM EPS was negative $1.38, while the forward P/E was 16.6945 and next-year EPS is estimated at $0.07. Those figures show a pet-care business with strong thematic purity but weak current economics.
Recent momentum. The earnings record is the clearest concern: PetMed Express beat estimates in 0 of the last 7 reported quarters. In August, it posted EPS of negative $0.28 against an estimate of $0.12, a negative 333.3% surprise; the February result was negative $0.50 versus negative $0.06, a negative 733.3% surprise. The consensus field is 1 and the stated average analyst target is $1.40, but the earnings history and negative returns on equity and assets make this the most speculative name in the countdown.
What they do. Trupanion provides subscription-based medical insurance for cats and dogs in the United States, Canada and Continental Europe. Its business serves both pet owners and veterinarians, giving it a recurring-revenue model rather than a product-only retail model. That subscription structure can make customer relationships more durable, while the insurance model also exposes the company to claims costs, pricing discipline and underwriting performance.
Why it fits. Pet insurance is one of the clearest ways to participate in the humanization-of-pets trend. Coverage can help owners manage increasingly expensive veterinary care and may support earlier or more consistent treatment, linking insurance to preventive care and the broader pet-health infrastructure. Trupanion’s specialized focus gives it deeper exposure than diversified retailers, though its economics are more sensitive to medical inflation and claims experience.
Numbers that matter. Revenue increased 11.1% year over year to $1.520755968 billion. Profitability is positive but still thin, with a 22.6% gross margin, 1.62% operating margin and 1.53% net margin; EBITDA was $40.739 million. TTM EPS was $0.53, while the trailing P/E was 56.8491 and the reported forward P/E was 1428.5714. The valuation therefore leaves little room for execution mistakes, particularly alongside an earnings-growth decline of 28.9%.
Recent momentum. Trupanion has beaten estimates in 3 of the last 7 reported quarters. The August quarter was encouraging, with EPS of $0.16 versus an estimate of $0.11, a 45.5% surprise, but April EPS of $0.78 trailed the $0.88 estimate by 11.4%. Four analysts are listed as Hold, producing a 3.6667 consensus score, and the average target is $33.25. That combination points to a credible growth niche, but not an unambiguous valuation case.
What they do. Petco operates a pet-specialty retail network across the United States, Mexico, Puerto Rico and Chile, combining products with veterinary care, grooming and training services. It sells consumables and supplies through stores, its website and mobile app, alongside private-label brands such as WholeHearted, Reddy, So Phresh and Well & Good. That blend of merchandise and services gives Petco a broader customer relationship than a conventional retailer, while also creating a demanding operating model.
Why it fits. Petco offers one of the most direct combinations of specialty retail and pet wellness in the list. Veterinary care, grooming and training can increase visit frequency and deepen customer engagement, while food, treats, supplies and private-label products address everyday ownership needs. Its omnichannel presence also fits the shift toward convenience, but the retailer remains exposed to consumer trade-downs, store productivity and the cost of delivering services.
Numbers that matter. Revenue was $5.9654912 billion, with EBITDA of $332.369 million. The company posted a 38.8% gross margin and 3.21% operating margin, but net margin was only 0.51% and return on equity was 2.58%. The trailing P/E was 26.1 versus a forward P/E of 9.5785, while EPS is estimated to rise from TTM EPS of $0.10 to $0.2111 next year. The low net margin shows how much execution is required to convert scale into durable shareholder returns.
Recent momentum. Petco has beaten estimates in 5 of the last 7 reported quarters. Its September quarter produced EPS of $0.13 against an estimate of $0.03, a 333.3% surprise, although the following two reported quarters matched estimates rather than exceeded them. The consensus score is 3.0833, with 1 Buy, 8 Holds and 2 Sells; the average target is $3.4691. The improving earnings pattern is constructive, but the narrow profit margin keeps the turnaround case sensitive to small changes in sales or costs.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Central Garden & Pet manufactures and distributes products across pet supplies and lawn and garden, with the pet business spanning dog and cat treats, toys, beds, grooming items, waste management, aquatics, small animals, reptiles, birds and animal health products. Its pet brands include Aqueon, Cadet, Comfort Zone, Farnam, Four Paws, K&H Pet Products, Kaytee, Nylabone and Zilla. The company sells through distributors, major retailers, e-commerce channels, grocery stores, nurseries and mass merchants, providing broad distribution but also leaving the group partly exposed to non-pet demand.
Why it fits. Central’s pet segment gives investors diversified exposure to supplies and consumables rather than a single product category. Treats, chews, food and supplements support recurring ownership spending, while aquatics, grooming, containment and waste-management products broaden participation in the full pet-care ecosystem. Its animal and household health products add a wellness angle, although the Garden segment means the company is less pure-play than the retailers, pharmacy and animal-health specialists ranked above it.
Numbers that matter. Revenue was $3.084065024 billion and EBITDA was $338.49 million. Central reported a 32.6% gross margin, 14.26% operating margin and 5.39% net margin, with return on equity of 9.97% and return on assets of 4.31%. The trailing P/E was 16.8815 and the forward P/E was 14.0647, while revenue declined 8.2% year over year and earnings declined 4.6%. Next-year EPS is estimated at $3.0893, suggesting a moderate recovery rather than a high-growth profile.
Recent momentum. Central has beaten estimates in all 7 of the last 7 reported quarters. August EPS was $1.54 versus $1.51 expected, a 2.0% surprise, while May EPS exceeded the estimate by 17.3%. The consensus score is 4.2, based on 1 Buy and 1 Sell in the supplied breakdown, with an average target of $53. That earnings consistency is a meaningful strength, but the negative recent revenue and earnings growth explain why the stock ranks below the more focused pet-health opportunities.
What they do. The J. M. Smucker Company manufactures and markets branded food and beverage products, including a dedicated U.S. Retail Pet Foods segment. Its pet portfolio includes Meow Mix, Milk-Bone, Pup-Peroni and Canine Carry Outs, with products sold through food retailers, club stores, online retailers, pet-specialty stores, drug stores and mass merchants. The company’s scale, established brands and broad distribution support its position in pet food and treats, although shareholders are also exposed to its coffee, snacks, spreads and other businesses.
Why it fits. Smucker is a useful way to access the branded pet-food and treat sub-segment without relying exclusively on pet care. Milk-Bone and the other named brands participate in high-frequency feeding and reward occasions, where brand familiarity and distribution can reinforce repeat purchasing. Its pet exposure is less comprehensive than that of a retailer or animal-health company, but the category’s necessity-like demand can complement the company’s broader consumer-staples portfolio.
Numbers that matter. Revenue reached $9.15689984 billion, with year-over-year revenue growth of 5.0% and EBITDA of $2.263899904 billion. Gross margin was 38.0% and operating margin was 17.9%, but net margin was 2.51% and return on equity was 3.93%. The reported trailing P/E was 60.7009 compared with a forward P/E of 12.3762; TTM EPS was $2.14 and next-year EPS is estimated at $8.7543. The large gap between the trailing and forward measures makes earnings normalization important to the valuation case.
Recent momentum. Smucker has beaten estimates in 5 of the last 7 reported quarters. In August, EPS was $3.24 versus $2.21 expected, a 46.6% surprise; June and February also produced positive surprises of 4.9% and 4.8%. The consensus score is 3.8947, with 3 Buys and 9 Holds, and the average target is $141.8125. The recent earnings record is better than the C+ grade alone suggests, but the 2.6% decline in earnings growth and diversified corporate structure temper the pet-care ranking.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The screen begins with US-listed companies and a market-cap threshold above $500 million, then ranks candidates first by the depth of their exposure to pet care and second by business fundamentals. Theme exposure includes pet food and treats, specialty and online retail, veterinary services, diagnostics, pharmaceuticals, parasiticides and insurance. Fundamental review incorporates the composite quality grade, profitability, revenue and earnings growth, valuation ratios, earnings surprises, balance-sheet signals and analyst consensus. The article is refreshed monthly, so market capitalization, valuation and consensus data can change between editions. The ranking is a countdown from #7 to #1, with #1 representing the strongest overall fit in this edition.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.